10-Q · May 12, 2026
Kura Oncology reported Q1 2026 results reflecting significant challenges, with revenues of $18.3 million falling short of estimates of $23.7 million, and an EPS loss of $0.83, slightly worse than the consensus loss of…
Earnings analysis · 10-Q
KURA earnings analysis
Filed August 12, 2026 · Our reading of the company's report
The latest report
Kura delivered $20.874 million of revenue and a $0.77 diluted EPS loss in the quarter, with revenue up approximately 16% sequentially and 39% year over year while the EPS loss improved sequentially. KOMZIFTI product…
Read full summary
Kura delivered $20.874 million of revenue and a $0.77 diluted EPS loss in the quarter, with revenue up approximately 16% sequentially and 39% year over year while the EPS loss improved sequentially. KOMZIFTI product revenue reached $9.1 million, up 57% quarter over quarter, supporting commercial momentum. However, Kura remains loss-making, has limited commercialization history, faces meaningful safety and reimbursement risks, and provided no explicit revenue or EPS guidance. Management’s liquidity outlook indicates $519.0 million of cash, cash equivalents and short-term investments plus $180.0 million of anticipated collaboration payments to fund the ziftomenib AML program through anticipated 2028 KOMET-017 topline results.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.77
- Segment
- KOMZIFTI net product revenue: $9.1 million, up 57% sequentially; no other segment revenue was disclosed.
What stood out
-
Revenue accelerated sequentially and year over year
Revenue was $20.874 million, up from $18 million in 2026 Q1 and $15 million in 2025 Q2, representing approximately 16% sequential growth and 39% year-over-year growth.
-
EPS loss improved sequentially
Diluted EPS was a loss of $0.77, improving from a loss of $0.83 in 2026 Q1 but worsening from a loss of $0.75 in 2025 Q2.
-
KOMZIFTI commercial momentum
KOMZIFTI generated $9.1 million of net product revenue, an increase of 57% quarter over quarter, and achieved a majority share of new patient starts in its class.
-
Substantial liquidity supports development
Liquidity included $519.0 million of cash, cash equivalents and short-term investments, with an additional $180.0 million in anticipated collaboration payments tied to the ziftomenib program.
-
Funding runway extends to 2028
Management stated that available liquidity is expected to fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.
-
Controls remained effective
Disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2026, and management reported no material changes in internal control over financial reporting during the quarter.
What to watch
-
Unproven commercial execution
The amended risk factor is particularly relevant as Kura only commenced KOMZIFTI commercialization in November 2025 and has no prior organizational experience commercializing an approved drug. KOMZIFTI is the company’s only approved product and is approved solely for adult patients with relapsed or refractory NPM1-mutated AML.
-
Coverage and pricing pressure
The amended reimbursement risk could constrain revenue because KOMZIFTI was approved in November 2025 and coverage and reimbursement for newly approved products remain uncertain. The filing notes that Medicare price negotiations can apply to single-source drugs that have been on the market for at least 7 years, while government and private-payor policies may affect pricing before then.
-
Material ziftomenib safety exposure
KOMZIFTI and ziftomenib carry material safety and post-approval risks. Treatment-related serious adverse event data include differentiation syndrome occurring in more than 10% of patients receiving ziftomenib monotherapy, and the FDA adjudicated 2 fatal cases in which differentiation syndrome could not be ruled out as a contributing factor.
-
Funding dependence and dilution
The company remains dependent on external financing despite reported liquidity. Its term-loan facility allows up to $125.0 million of term loans, but only $10.0 million was borrowed and no further draws are available; it also maintains an ATM facility permitting up to $150.0 million of equity sales, creating potential dilution if used.
-
Tariffs threaten supply and costs
The amended trade-policy risk is material because Kura relies on third-party manufacturers and suppliers, including suppliers located in China, while the filing states that tariffs could increase research and development expenses and disrupt the supply chain. The company does not own manufacturing facilities and has no current plans to build clinical or commercial-scale manufacturing capabilities.
-
Expanding data-security exposure
The amended data-privacy and security risk includes potential regulatory fines and litigation involving sensitive patient and clinical-trial data. The filing cites potential GDPR penalties of up to €20 million or 4% of annual global revenue, whichever is greater, and notes a cybersecurity incident at a former clinical-trial service provider in July 2024.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that $519.0 million of cash, cash equivalents and short-term investments, plus $180.0 million in anticipated collaboration payments, is expected to fund the ziftomenib AML program through topline results from the first pivotal Phase 3 KOMET-017 trial, anticipated in 2028.
Earlier filings 4
10-K · March 5, 2026
Kura Oncology, Inc. has experienced a challenging year ending December 31, 2025, with a significant net loss of approximately $278.7 million amid the commercial launch of its product KOMZIFTI, alongside substantial…
10-Q · November 4, 2025
Kura Oncology's Q3 2025 10-Q reveals significant challenges with revenue and EPS falling short of expectations. Total revenue came in at $21 million, substantially lower than the anticipated $62 million, and EPS…
10-Q · August 7, 2025
Kura Oncology's latest 10-Q reflects a continued struggle as reported Q2 revenue of $15 million falls significantly below the estimated $95.7 million, marking a steep decline from previous quarters. EPS also…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.